1[1]Uhoda I, Quatresooz P, Hermanns-Le T, et al. Histometric assessment of psoriatic plaques treated by vitamin D3 derivatives[J]. Dermatology, 2003,206(4):366-369.
2[2]Bruner CR, Feldman SR, Ventrapragada M, et al.A systematic review of adverse effects associated with topical treatments for psoriasis[J]. Dermatol Online J,2003,9(1):2.
3[3]Katayama I, Ohkawara A, Ohkido M, et al. High-concentration(20 μg/g) tacalcitol ointment therapy on refractory psoriasis vulgaris with low response to topical corticosteroids[J]. Eur J Dermatol, 2002,12(6):553-557.
4[4]Miyachi Y, Ohkawara A, Ohkido M, et al. Long-term safety and efficacy of high-concentration (20 μg/g) tacalcitol ointment in psoriasis vulgaris[J]. EurJ Dermatol, 2002,12(5):463-468.
5[5]Lambert J, Trompke C. Tacalcitol ointment for long-term control of chronic plaque psoriasis in dermatological practice[J]. Dermatology,2002,204(4):321-324.
5Seston EN, Ashcroft DM, Griffiths CE. Balancing the benefits and risks of drug treatment: a stated-preference, discrete choice experiment with patients with psoriasis [J]. Arch Dermatol,2007, 143(9):1175-1179.
6Lebwohl M.A clinician's paradigm in the treatment of psoriasis[J]. J Am Acad Dermatol,2005,53(Suppl):59-69.
